Identification

Name
Valdecoxib
Accession Number
DB00580  (APRD00183, DB07576)
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Bextra
Categories
UNII
2919279Q3W
CAS number
181695-72-7
Weight
Average: 314.359
Monoisotopic: 314.072513014
Chemical Formula
C16H14N2O3S
InChI Key
LNPDTQAFDNKSHK-UHFFFAOYSA-N
InChI
InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
IUPAC Name
4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide
SMILES
CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O

Pharmacology

Indication

For the treatment of osteoarthritis and dysmenorrhoea

Pharmacodynamics

Valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Valdecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, valdecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism.

Mechanism of action

Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 3
inhibitor
Human
Absorption

Oral bioavailability is 83%.

Volume of distribution
  • 86 L
Protein binding

98%

Metabolism

Hepatic (involves CYP3A4 and 2C9)

Route of elimination

Valdecoxib is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces. About 70% of the dose is excreted in the urine as metabolites, and about 20% as valdecoxib N-glucuronide.

Half life

8-11 hours

Clearance
  • oral cl=6 L/h
  • 6 – 7 L/h [In patients undergoing hemodialysis]
  • 6 – 7 L/h [healthy elderly subjects]
Toxicity

Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Valdecoxib Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Valdecoxib.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 5-androstenedione.Experimental, Illicit
AbciximabValdecoxib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Valdecoxib can be decreased when combined with Abiraterone.Approved
AcebutololValdecoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolValdecoxib may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Acetaminophen.Approved
Acetyl sulfisoxazoleThe metabolism of Valdecoxib can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Valdecoxib.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Valdecoxib.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Valdecoxib.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Valdecoxib.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid.Approved
AliskirenValdecoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Valdecoxib.Experimental
AlprenololValdecoxib may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Valdecoxib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Amcinonide.Approved
AmikacinValdecoxib may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideValdecoxib may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Valdecoxib can be decreased when combined with Amiodarone.Approved, Investigational
AncrodValdecoxib may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Valdecoxib.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Valdecoxib.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Antipyrine.Approved, Investigational
Antithrombin III humanValdecoxib may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Valdecoxib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanValdecoxib may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Valdecoxib.Investigational
ApramycinValdecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Valdecoxib.Approved, Investigational
AprepitantThe serum concentration of Valdecoxib can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinValdecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinValdecoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanValdecoxib may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololValdecoxib may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineValdecoxib may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Atamestane.Investigational
AtazanavirThe metabolism of Valdecoxib can be decreased when combined with Atazanavir.Approved, Investigational
AtenololValdecoxib may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Valdecoxib can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Valdecoxib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Valdecoxib.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Valdecoxib.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Valdecoxib.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Balsalazide.Approved, Investigational
BazedoxifeneValdecoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminValdecoxib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololValdecoxib may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinValdecoxib may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Valdecoxib.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Valdecoxib.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Valdecoxib.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Valdecoxib.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Valdecoxib.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Valdecoxib.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Valdecoxib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Betamethasone.Approved, Vet Approved
BetaxololValdecoxib may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Valdecoxib.Approved, Investigational
BevantololValdecoxib may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Valdecoxib.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Valdecoxib.Approved, Investigational
BisoprololValdecoxib may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinValdecoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Valdecoxib can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololValdecoxib may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Valdecoxib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Valdecoxib can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Valdecoxib.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Valdecoxib.Investigational
BucindololValdecoxib may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Bufexamac.Approved, Experimental
BufuralolValdecoxib may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Valdecoxib.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Valdecoxib.Approved
BupranololValdecoxib may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Valdecoxib.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Valdecoxib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Valdecoxib can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Captopril.Approved
CarbamazepineThe metabolism of Valdecoxib can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Valdecoxib.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Valdecoxib.Approved
CarprofenThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololValdecoxib may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolValdecoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Valdecoxib.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Valdecoxib.Approved, Investigational
CeliprololValdecoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Valdecoxib can be increased when it is combined with Ceritinib.Approved
CertoparinValdecoxib may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Valdecoxib.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
ChlorotrianiseneValdecoxib may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Valdecoxib.Approved
CholecalciferolThe metabolism of Valdecoxib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Valdecoxib.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cimicoxib.Investigational
CinoxacinValdecoxib may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinValdecoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Valdecoxib.Approved
Citric AcidValdecoxib may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Valdecoxib can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Valdecoxib can be decreased when combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Valdecoxib.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Valdecoxib.Vet Approved
CloranololValdecoxib may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneValdecoxib may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Valdecoxib can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Valdecoxib can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Valdecoxib.Approved, Investigational
Conjugated estrogensValdecoxib may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Valdecoxib can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Valdecoxib can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Valdecoxib.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Valdecoxib.Experimental
CyclosporineValdecoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateValdecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Valdecoxib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinValdecoxib may increase the thrombogenic activities of Daidzein.Experimental
DalteparinValdecoxib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidValdecoxib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Valdecoxib.Investigational
DarexabanValdecoxib may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Valdecoxib can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Valdecoxib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Valdecoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Delapril.Experimental
DelavirdineThe metabolism of Valdecoxib can be decreased when combined with Delavirdine.Approved
DesipramineValdecoxib may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinValdecoxib may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Valdecoxib.Approved, Investigational
DextranValdecoxib may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinValdecoxib may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Valdecoxib.Approved, Vet Approved
DicoumarolValdecoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolValdecoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolValdecoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Valdecoxib.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Valdecoxib.Approved
DihydroergotamineThe metabolism of Valdecoxib can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydrostreptomycinValdecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Valdecoxib can be decreased when combined with Diltiazem.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Valdecoxib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Valdecoxib.Approved
DiphenadioneValdecoxib may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe metabolism of Valdecoxib can be decreased when combined with Dosulepin.Approved
DoxycyclineThe metabolism of Valdecoxib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Valdecoxib can be decreased when combined with Dronedarone.Approved
DrospirenoneValdecoxib may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Valdecoxib.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Valdecoxib.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Valdecoxib.Investigational
Edetic AcidValdecoxib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanValdecoxib may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Valdecoxib can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Enalaprilat.Approved
EnoxacinValdecoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinValdecoxib may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Valdecoxib.Experimental
EnzalutamideThe serum concentration of Valdecoxib can be decreased when it is combined with Enzalutamide.Approved
EpanololValdecoxib may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolValdecoxib may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Valdecoxib.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Valdecoxib.Experimental
EplerenoneValdecoxib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Valdecoxib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Valdecoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Equilin.Approved
EquolValdecoxib may increase the thrombogenic activities of Equol.Investigational
ErythromycinThe metabolism of Valdecoxib can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololValdecoxib may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
EsmololValdecoxib may decrease the antihypertensive activities of Esmolol.Approved
EstradiolValdecoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateValdecoxib may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateValdecoxib may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateValdecoxib may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolValdecoxib may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedValdecoxib may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneValdecoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Valdecoxib.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Valdecoxib.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Valdecoxib.Experimental
Ethinyl EstradiolValdecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateValdecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Valdecoxib.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Valdecoxib.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Valdecoxib can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Valdecoxib.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Valdecoxib.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Valdecoxib.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Valdecoxib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Valdecoxib.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Valdecoxib.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Valdecoxib.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Valdecoxib.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Valdecoxib.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Valdecoxib.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fish oil.Approved, Nutraceutical
FleroxacinValdecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Valdecoxib.Approved, Withdrawn
FloxuridineThe metabolism of Valdecoxib can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Valdecoxib can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fludrocortisone.Approved, Investigational
FluindioneValdecoxib may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineValdecoxib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Valdecoxib.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Valdecoxib.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Valdecoxib.Approved, Investigational
FluorouracilThe metabolism of Valdecoxib can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Valdecoxib.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Valdecoxib.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Valdecoxib.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Valdecoxib can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Valdecoxib.Approved, Nutraceutical, Vet Approved
FondaparinuxValdecoxib may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumValdecoxib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Valdecoxib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Valdecoxib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Valdecoxib can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Valdecoxib can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinValdecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
Fusidic AcidThe serum concentration of Valdecoxib can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateValdecoxib may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinValdecoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinValdecoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Valdecoxib.Approved, Withdrawn
GemfibrozilThe metabolism of Valdecoxib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinValdecoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinValdecoxib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinValdecoxib may increase the thrombogenic activities of Genistein.Investigational
GentamicinValdecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AValdecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinValdecoxib may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Valdecoxib.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Valdecoxib is combined with HE3286.Investigational
HeparinValdecoxib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolValdecoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Valdecoxib.Investigational
HydralazineValdecoxib may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Valdecoxib.Approved, Investigational
Hygromycin BValdecoxib may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Valdecoxib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Valdecoxib.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Valdecoxib can be decreased when combined with Idelalisib.Approved
IdraparinuxValdecoxib may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Valdecoxib.Approved, Investigational
ImatinibThe metabolism of Valdecoxib can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Valdecoxib.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Valdecoxib.Approved
IndenololValdecoxib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Valdecoxib can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Valdecoxib.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Valdecoxib.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Valdecoxib.Withdrawn
IrbesartanThe metabolism of Valdecoxib can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Valdecoxib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Valdecoxib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinValdecoxib may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Valdecoxib.Withdrawn
IsradipineThe metabolism of Valdecoxib can be decreased when combined with Isradipine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Valdecoxib can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Valdecoxib can be increased when it is combined with Ivacaftor.Approved
KanamycinValdecoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Valdecoxib.Experimental
KetoconazoleThe metabolism of Valdecoxib can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Valdecoxib.Approved
LabetalolValdecoxib may decrease the antihypertensive activities of Labetalol.Approved
LandiololValdecoxib may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Valdecoxib.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Valdecoxib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Valdecoxib.Approved, Investigational
LepirudinValdecoxib may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanValdecoxib may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololValdecoxib may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololValdecoxib may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinValdecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Valdecoxib.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Valdecoxib.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Valdecoxib.Approved
LobeglitazoneThe metabolism of Valdecoxib can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinValdecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Valdecoxib.Experimental
LopinavirThe metabolism of Valdecoxib can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Valdecoxib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Valdecoxib can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Loteprednol.Approved
LovastatinThe metabolism of Valdecoxib can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Valdecoxib.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Valdecoxib.Approved, Investigational
LuliconazoleThe serum concentration of Valdecoxib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Valdecoxib can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Valdecoxib.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Valdecoxib can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Valdecoxib.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Valdecoxib is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Mefenamic acid.Approved
MelagatranValdecoxib may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Meloxicam.Approved, Vet Approved
MepindololValdecoxib may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Valdecoxib.Approved
MestranolValdecoxib may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Valdecoxib.Approved, Investigational, Withdrawn
MethallenestrilValdecoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Valdecoxib.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Valdecoxib.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Methylprednisolone.Approved, Vet Approved
MetipranololValdecoxib may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Valdecoxib.Approved
MetoprololValdecoxib may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinValdecoxib may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Valdecoxib can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Valdecoxib.Approved, Experimental
MifepristoneThe serum concentration of Valdecoxib can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Valdecoxib.Approved
MitotaneThe serum concentration of Valdecoxib can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Valdecoxib.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Valdecoxib.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Valdecoxib.Approved
MoxestrolValdecoxib may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinValdecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Valdecoxib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Valdecoxib.Approved
NabiloneThe metabolism of Valdecoxib can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Valdecoxib.Approved
NadololValdecoxib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinValdecoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Valdecoxib.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Valdecoxib.Approved
Nalidixic AcidValdecoxib may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Valdecoxib is combined with NCX 1022.Investigational
NeamineValdecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololValdecoxib may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Valdecoxib can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Valdecoxib can be decreased when combined with Nelfinavir.Approved
NemonoxacinValdecoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinValdecoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Valdecoxib.Approved, Investigational
NetilmicinValdecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Valdecoxib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Valdecoxib can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Valdecoxib can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Valdecoxib.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Valdecoxib can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Valdecoxib.Investigational
NorfloxacinValdecoxib may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinValdecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Valdecoxib can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Valdecoxib.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Valdecoxib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Valdecoxib.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Valdecoxib is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Valdecoxib can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Valdecoxib.Vet Approved
OsimertinibThe serum concentration of Valdecoxib can be increased when it is combined with Osimertinib.Approved
OtamixabanValdecoxib may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Oxaprozin.Approved
Oxolinic acidValdecoxib may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololValdecoxib may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Valdecoxib.Approved, Withdrawn
PalbociclibThe serum concentration of Valdecoxib can be increased when it is combined with Palbociclib.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Valdecoxib.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Parecoxib.Approved
ParomomycinValdecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Valdecoxib.Approved, Investigational
PazufloxacinValdecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinValdecoxib may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololValdecoxib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateValdecoxib may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Valdecoxib can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateValdecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Perindopril.Approved
PhenindioneValdecoxib may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Valdecoxib can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonValdecoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Valdecoxib can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Valdecoxib.Approved, Investigational
PindololValdecoxib may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidValdecoxib may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Valdecoxib.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Valdecoxib.Approved, Investigational
Piromidic acidValdecoxib may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Valdecoxib.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Valdecoxib.Experimental
PitolisantThe serum concentration of Valdecoxib can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorValdecoxib may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinValdecoxib may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
Polyestradiol phosphateValdecoxib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Valdecoxib.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Valdecoxib can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitrateValdecoxib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololValdecoxib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Valdecoxib.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Valdecoxib.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Valdecoxib can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Valdecoxib can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Valdecoxib.Experimental
PromestrieneValdecoxib may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Valdecoxib.Approved, Investigational
PropafenoneValdecoxib may decrease the antihypertensive activities of Propafenone.Approved
PropranololValdecoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Valdecoxib.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Valdecoxib.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Valdecoxib.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Valdecoxib.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Valdecoxib.Vet Approved
Protein CValdecoxib may increase the anticoagulant activities of Protein C.Approved
Protein S humanValdecoxib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeValdecoxib may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinValdecoxib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Valdecoxib.Investigational
PuromycinValdecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Valdecoxib can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Quinapril.Approved, Investigational
QuinestrolValdecoxib may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Valdecoxib.Approved
QuinineThe metabolism of Valdecoxib can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ramipril.Approved
RanolazineThe metabolism of Valdecoxib can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinValdecoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinValdecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Valdecoxib can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Valdecoxib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Valdecoxib can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Risedronate.Approved, Investigational
RivaroxabanValdecoxib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Valdecoxib.Approved, Investigational, Withdrawn
RosoxacinValdecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Valdecoxib can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinValdecoxib may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Valdecoxib.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Valdecoxib.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Valdecoxib.Experimental
SaquinavirThe metabolism of Valdecoxib can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Valdecoxib.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Valdecoxib.Approved, Investigational
SecobarbitalThe metabolism of Valdecoxib can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolValdecoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Valdecoxib.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Valdecoxib.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Valdecoxib.Investigational
SertralineSertraline may increase the antiplatelet activities of Valdecoxib.Approved
SildenafilThe metabolism of Valdecoxib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Valdecoxib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Valdecoxib can be increased when it is combined with Simeprevir.Approved
SisomicinValdecoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinValdecoxib may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateValdecoxib may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Valdecoxib.Approved
SorafenibThe metabolism of Valdecoxib can be decreased when combined with Sorafenib.Approved, Investigational
SotalolValdecoxib may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinValdecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Spirapril.Approved
SpironolactoneValdecoxib may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Valdecoxib.Investigational
St. John's WortThe serum concentration of Valdecoxib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Valdecoxib can be increased when it is combined with Stiripentol.Approved
StreptomycinValdecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineThe metabolism of Valdecoxib can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Valdecoxib can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Valdecoxib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Sulindac.Approved, Investigational
SulodexideValdecoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Valdecoxib.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Valdecoxib.Experimental
Synthetic Conjugated Estrogens, AValdecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BValdecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusValdecoxib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Valdecoxib.Approved
TalinololValdecoxib may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Valdecoxib.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Valdecoxib.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Valdecoxib.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Valdecoxib can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Valdecoxib can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Valdecoxib.Approved, Investigational
TemafloxacinValdecoxib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Valdecoxib.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Valdecoxib.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Valdecoxib.Vet Approved
TerbutalineValdecoxib may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Valdecoxib.Approved
TertatololValdecoxib may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tiaprofenic acid.Approved
TiboloneValdecoxib may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Valdecoxib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Valdecoxib can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololValdecoxib may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Valdecoxib.Investigational
TioclomarolValdecoxib may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tixocortol.Approved, Withdrawn
TobramycinValdecoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Valdecoxib can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Valdecoxib can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Valdecoxib.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Valdecoxib.Approved
TopiroxostatThe metabolism of Valdecoxib can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Valdecoxib.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Valdecoxib.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Valdecoxib.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Valdecoxib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneValdecoxib may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Valdecoxib.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
TrimethoprimThe metabolism of Valdecoxib can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Valdecoxib.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Trolamine salicylate.Approved
TrovafloxacinValdecoxib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinValdecoxib may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Valdecoxib.Approved, Investigational
Valproic AcidThe metabolism of Valdecoxib can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Valdecoxib can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Valdecoxib.Approved
VemurafenibThe serum concentration of Valdecoxib can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Valdecoxib.Approved
VerapamilThe metabolism of Valdecoxib can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Valdecoxib can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinValdecoxib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranValdecoxib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Valdecoxib can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Valdecoxib.Approved, Investigational
ZeranolValdecoxib may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Valdecoxib.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Valdecoxib.Withdrawn
ZiprasidoneThe metabolism of Valdecoxib can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Valdecoxib.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Eswaraiah Sajja, Anumula Reddy, Aalla Sampath, Gilla Goverdhan, "Process for preparing crystalline form A of valdecoxib." U.S. Patent US20050272787, issued December 08, 2005.

US20050272787
General References
Not Available
External Links
Human Metabolome Database
HMDB0005033
PubChem Compound
119607
PubChem Substance
46506229
ChemSpider
106796
BindingDB
13063
ChEBI
63634
ChEMBL
CHEMBL865
Therapeutic Targets Database
DAP001541
PharmGKB
PA10226
HET
COX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Valdecoxib
ATC Codes
M01AH03 — Valdecoxib
PDB Entries
2aw1
FDA label
Download (82.8 KB)
MSDS
Download (70.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2CompletedTreatmentPain1
2, 3TerminatedPreventionERCP / Pancreatitis1
3CompletedTreatmentHallux Valgus / Pain1
3CompletedTreatmentKnee / Osteoarthritis (OA)1
3CompletedTreatmentLaparoscopic Cholecystectomy / Pain1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPain2
3CompletedTreatmentPain, Post-Surgical1
3CompletedTreatmentPharyngitis1
3CompletedTreatmentPostoperative pain2
3TerminatedTreatmentPain1
4CompletedPreventionHyperalgesia / Pain1
4CompletedTreatmentDysmenorrhea1
4CompletedTreatmentLow Back Pain (LBP)1
4CompletedTreatmentNeurosurgery / Pain1
4CompletedTreatmentPain / Sprains / Sprains and Strains1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentRupture of Anterior Cruciate Ligament1
4TerminatedTreatmentPain, Acute1
4TerminatedTreatmentPost Surgical Pain1
Not AvailableCompletedBasic SciencePlatelet Aggregation1
Not AvailableCompletedSupportive CarePain / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentPostoperative pain1

Pharmacoeconomics

Manufacturers
  • Gd searle llc
Packagers
  • Cardinal Health
  • GD Searle LLC
  • Murfreesboro Pharmaceutical Nursing Supply
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Physicians Total Care Inc.
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7135489No1997-08-122017-08-12Us
US5633272No1995-02-132015-02-13Us
CA2212836No2003-08-122016-02-12Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0348 mg/mLALOGPS
logP3.32ALOGPS
logP2.82ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)10.06ChemAxon
pKa (Strongest Basic)0.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.19 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity84.71 m3·mol-1ChemAxon
Polarizability31.76 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9386
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.8864
P-glycoprotein inhibitor INon-inhibitor0.8772
P-glycoprotein inhibitor IINon-inhibitor0.9157
Renal organic cation transporterNon-inhibitor0.8576
CYP450 2C9 substrateNon-substrate0.7356
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6501
CYP450 1A2 substrateNon-inhibitor0.5759
CYP450 2C9 inhibitorInhibitor0.5385
CYP450 2D6 inhibitorNon-inhibitor0.8875
CYP450 2C19 inhibitorInhibitor0.5958
CYP450 3A4 inhibitorNon-inhibitor0.8652
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7649
Ames testNon AMES toxic0.8277
CarcinogenicityNon-carcinogens0.7399
BiodegradationNot ready biodegradable0.9948
Rat acute toxicity2.0680 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9708
hERG inhibition (predictor II)Non-inhibitor0.8652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0439000000-984ffa23e74fb8949b56
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0439000000-8928b5e8f850f43f1430
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0089-2930000000-dac70ddadd2ffd150b22

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Organosulfonamides / Isoxazoles / Heteroaromatic compounds / Aminosulfonyl compounds / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds
show 2 more
Substituents
Benzenesulfonamide / Benzenesulfonyl group / Organosulfonic acid amide / Azole / Isoxazole / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Heteroaromatic compound / Aminosulfonyl compound / Sulfonyl
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, isoxazoles (CHEBI:63634)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K: 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000 Mar 9;43(5):775-7. [PubMed:10715145]
  2. Jain KK: Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Investig Drugs. 2000 Nov;9(11):2717-23. [PubMed:11060833]
  3. Yuan JJ, Yang DC, Zhang JY, Bible R Jr, Karim A, Findlay JW: Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab Dispos. 2002 Sep;30(9):1013-21. [PubMed:12167567]
  4. Tacconelli S, Capone ML, Sciulli MG, Ricciotti E, Patrignani P: The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin. 2002;18(8):503-11. [PubMed:12564662]
  5. Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, Monahan JB: Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol. 2003 Apr;63(4):870-7. [PubMed:12644588]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K: Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19. [PubMed:15494548]
Details
2. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]
Details
3. Carbonic anhydrase 3
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA3
Uniprot ID
P07451
Uniprot Name
Carbonic anhydrase 3
Molecular Weight
29557.215 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 06:37